Rydar Equities’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.12M Buy
1,783
+208
+13% +$245K 1.09% 30
2026
Q2
$1.85M Buy
1,575
+10
+0.6% +$10.2K 1.04% 36
2026
Q1
$1.44M Buy
1,565
+3
+0.2% +$3.04K 1.11% 32
2025
Q4
$1.68M Buy
1,562
+4
+0.3% +$3.82K 1.31% 26
2025
Q3
$1.31M Sell
1,558
-45
-3% -$33.5K 1.05% 31
2025
Q2
$1.25M Buy
+1,603
New +$1.25M 0.99% 33

Other funds holding LLY

Rydar Equities's LLY Position: Q3 2026 in Review

Rydar Equities increased its Eli Lilly (LLY) stake by 13% in Q3 2026, buying an estimated $245K and bringing the position to 1,783 shares worth $2.12M. The position accounts for 1.09% of the portfolio, ranked #30.

Rydar Equities first reported a position in LLY in Q2 2025 and has held it in 6 quarters since. 904 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Rydar Equities held 1,783 shares of Eli Lilly worth $2.12M as of Q3 2026.
  • Rydar Equities bought 208 Eli Lilly shares in Q3 2026, an estimated $245K.
  • Eli Lilly made up 1.09% of Rydar Equities's portfolio in Q3 2026, its #30 holding.
  • Rydar Equities first reported a position in Eli Lilly in Q2 2025 and has held it in 6 quarters since.
  • 904 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.